Toni K. Choueiri

Also affiliated with Dana-Farber Cancer Institute

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.1Author DataRank

Indexed papers

8in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 8 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes

ESMO Open(2025)10.1016/j.esmoop.2024.104105

Top 42%

0.448DataRank

Top 42%11 citations

G. G. Birch, Alia Meliki, V Moritz, Mausumi Bharadwaj, Nicholas R. Schindler +20 more

Papers

Driven by 113 papers — median percentile 46. Top paper: “Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study”.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

The Lancet(2020)10.1016/s0140-6736(20)31187-9

N/A

11.9DataRank · unranked

1804 citations

Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera +95 more

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

Cancer Cell(2021)10.1016/j.ccell.2021.02.013

N/A

9.5DataRank · unranked

526 citations

Kelly Street, Kelly P. Burke, David L. Cookmeyer, Thomas Denize, Christina B. Pedersen +30 more

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Annals of Oncology(2021)10.1016/j.annonc.2021.02.024

N/A

6.8DataRank · unranked

328 citations

Ali Raza Khaki, Trisha M. Wise‐Draper, Benjamin French, Conor Hennessy, Chih–Yuan Hsu +95 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

ESMO Open(2020)10.1136/esmoopen-2020-001079

N/A

6.4DataRank · unranked

524 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +15 more

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000891

N/A

5.8DataRank · unranked

225 citations

Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles +24 more

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer(2022)10.1002/cncr.34180

N/A

5.5DataRank · unranked

265 citations

David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies

Cancer(2020)10.1002/cncr.33328

N/A

3.1DataRank · unranked

113 citations

Matthew T. Campbell, Wanling Xie, Subrina Farah, Mehmet Asım Bilen, Andrew Schmidt +11 more

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005445

N/A

2.7DataRank · unranked

69 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Saby George +9 more

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

European Urology(2021)10.1016/j.eururo.2021.10.001

N/A

2.6DataRank · unranked

80 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +17 more

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

ESMO Open(2024)10.1016/j.esmoop.2024.102994

N/A

1.9DataRank · unranked

94 citations

Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah +15 more

Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

The Lancet Oncology(2024)10.1016/s1470-2045(24)00211-0

N/A

1.9DataRank · unranked

86 citations

Se-Eun Kim, Viraj A. Master, David H. McDermott, Lauren C. Harshman, Suzanne Cole +40 more

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19

JAMA Oncology(2022)10.1001/jamaoncol.2022.5357

N/A

1.5DataRank · unranked

63 citations

Chris Labaki, Punita Grover, Joy Awosika, Shuchi Gulati, Chih–Yuan Hsu +95 more

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)00913-3

N/A

1.4DataRank · unranked

49 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +14 more

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Cancer Cell(2021)10.1016/j.ccell.2021.02.015

N/A

0.964DataRank · unranked

617 citations

Meng Xiao He, Ziad Bakouny, Abhay Kanodia, Sara Napolitano, Jingyi Wu +26 more

Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.03.019

N/A

0.848DataRank · unranked

20 citations

Michael B. Atkins, Toni K. Choueiri, Despina Thomaidou, Brad Rosbrook, M. Thakur +2 more

Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial

European Journal of Cancer(2022)10.1016/j.ejca.2022.09.020

N/A

0.795DataRank · unranked

18 citations

Thomas Powles, Bernard Escudier, Mauricio Burotto, Joshua Zhang, Burçin Şimşek +4 more

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma

Nature Communications(2021)10.1038/s41467-021-21068-9

N/A

0.770DataRank · unranked

169 citations

David A. Braun, Sachet A. Shukla, Wenting Pan, Xīn Gào, Yue Hou +48 more

Testicular Cancer, Version 2.2015

Journal of the National Comprehensive Cancer Network(2015)10.6004/jnccn.2015.0092

N/A

0.732DataRank · unranked

131 citations

Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger +27 more

Shareable artificial intelligence to extract cancer outcomes from electronic health records for precision oncology research

Nature Communications(2024)10.1038/s41467-024-54071-x

N/A

0.724DataRank · unranked

21 citations

Justin Jee, Karl Pichotta, Megan Paul, Pavel Trukhanov, Christopher J. Fong +8 more

Liquid biopsy epigenomic profiling for cancer subtyping

Nature Medicine(2023)10.1038/s41591-023-02605-z

N/A

0.722DataRank · unranked

122 citations

Ji-Heui Seo, Matthew P. Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian +38 more

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

Annals of Oncology(2025)10.1016/j.annonc.2025.09.006

N/A

0.719DataRank · unranked

18 citations

Bernard Escudier, Mauricio Burotto, Thomas Powles, Andrea B. Apolo, María T. Bourlon +16 more

Integrative clinical and molecular characterization of translocation renal cell carcinoma

Cell Reports(2022)10.1016/j.celrep.2021.110190

N/A

0.717DataRank · unranked

118 citations

Ananthan Sadagopan, Praful Ravi, Nebiyou Y. Metaferia, Jiao Li, Shatha AbuHammad +35 more

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

Cancer Cell(2022)10.1016/j.ccell.2022.08.022

N/A

0.717DataRank · unranked

118 citations

Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W. Akl +27 more

Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors

Cancer Immunology Research(2020)10.1158/2326-6066.cir-19-0866

N/A

0.657DataRank · unranked

79 citations

Amin H. Nassar, Wanling Xie, Ziad Bakouny, Jacob E. Berchuck, David A. Braun +27 more

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009495

N/A

0.615DataRank · unranked

19 citations

Opeyemi A. Jegede, Elizabeth R. Plimack, Thomas Powles, Robert J. Motzer, Nizar M. Tannir +13 more

Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5023

N/A

0.599DataRank · unranked

12 citations

Opeyemi A. Jegede, Miriam Sant’Angelo, Sonia Moreno, David A. Braun, Megan Wind‐Rotolo +15 more

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3089

N/A

0.587DataRank · unranked

49 citations

Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae‐Lyun Lee +26 more

Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa064

N/A

0.557DataRank · unranked

40 citations

Michael B. Atkins, Ziad Bakouny, Maria I. Carlo, Charles G. Drake, Eric Jonasch +15 more

First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape

The Oncologist(2022)10.1093/oncolo/oyab056

N/A

0.510DataRank · unranked

29 citations

Chris Labaki, Georgia Sofia Karachaliou, Toni K. Choueiri, Tian Zhang, Shuchi Gulati

Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes

ESMO Open(2025)10.1016/j.esmoop.2024.104105

Top 42%

0.448DataRank

Top 42%11 citations

G. G. Birch, Alia Meliki, V Moritz, Mausumi Bharadwaj, Nicholas R. Schindler +20 more

Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008724

Top 44%

0.427DataRank

Top 44%8 citations

Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame +28 more

Targeting of HIF2-driven cachexia in kidney cancer

Nature Medicine(2025)10.1038/s41591-025-04054-2

N/A

0.419DataRank · unranked

9 citations

Laura Stransky, Nikita Bhalerao, Nitin H. Shirole, Qinqin Jiang, Eddy Saad +15 more

Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States

JAMA Network Open(2022)10.1001/jamanetworkopen.2021.42046

N/A

0.373DataRank · unranked

11 citations

Tianyi Sun, David D. Chism, Narjust Duma, Julie Fu, Na Tosha Gatson +87 more

Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma

European Urology Open Science(2024)10.1016/j.euros.2024.02.006

N/A

0.345DataRank · unranked

9 citations

Sabrina Y. Camp, Hoyin Chu, Ryan L. Collins, Riaz Gillani, Jihye Park +11 more

PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5101

N/A

0.330DataRank · unranked

8 citations

Mäneka Puligandla, Mohamad E. Allaf, David F. McDermott, Charles G. Drake, Sabina Signoretti +15 more

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Cancer Cell(2025)10.1016/j.ccell.2025.05.009

N/A

0.330DataRank · unranked

8 citations

Meng Xiao He, Ziad Bakouny, Abhay Kanodia, Sara Napolitano, Jingyi Wu +25 more

A Foundation Model for Spatial Proteomics

arXiv (Cornell University)(2025)10.48550/arxiv.2506.03373

N/A

0.292DataRank · unranked

6 citations

Yuzhou Chang, Huaying Qiu, Yao Yu Yeo, Guillaume Jaume, Yuchen Wang +55 more

A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma

The Oncologist(2024)10.1093/oncolo/oyad298

N/A

0.269DataRank · unranked

5 citations

Katharina Leucht, Wanling Xie, Opeyemi Jegede, David A Braun, Michael B. Atkins +3 more

Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma

Journal of Clinical Investigation(2026)10.1172/jci195725

N/A

0.241DataRank · unranked

4 citations

Karl Semaan, Jiao Li, Ze Zhang, Prathyusha Konda, Ananthan Sadagopan +27 more

Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e16521

Top 65%

0.198DataRank

Top 65%2 citations

Maheetha Bharadwaj, Grace Birch, Nicholas Schindler, Chris Labaki, Renée Maria Saliby +13 more

Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5010

N/A

0.165DataRank · unranked

2 citations

Yue Hou, Ziad Bakouny, Miriam Ficial, Miriam Sant’Angelo, Petra Ross‐Macdonald +15 more

COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease

Translational Oncology(2023)10.1016/j.tranon.2023.101709

N/A

0.115DataRank · unranked

1 citations

Cassandra Hennessy, Benjamin French, Jeremy L. Warner, Matthew D. Tucker, Daniel Hausrath +62 more

Immune Spatial Organization Predicts Metastasis Risk in Aggressive Localized Prostate Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.05.15.654324

N/A

0.104DataRank · unranked

1 citations

Anwar Abdelnaser, Jeremiah A. Wala, Alexander J Haas, Alfred A. Barney, Eddy Saad +12 more

Evaluation of statin use and renal cell carcinoma risk identifies sex-specific associations with RCC subtypes

Acta Oncologica(2023)10.1080/0284186x.2023.2238883

N/A

0.104DataRank · unranked

1 citations

Rebecca E. Graff, Alejandro Sánchez, Toni K. Choueiri, Eunyoung Cho, Mark A. Preston +2 more

Integrative clinical, genomic, and transcriptomic characterization of circulating KIM-1 in metastatic RCC.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.4546

N/A

0.104DataRank · unranked

1 citations

Renée Maria Saliby, Eddy Saad, Clara Steiner, Caiwei Zhong, Emre Yekedüz +15 more

Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0466

N/A

0DataRank · unranked

32 citations

Catherine B. Meador, Xintao Qiu, Ji-Heui Seo, Matthew P. Davidsohn, Hunter Savignano +20 more

Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma

Journal of Clinical Investigation(2024)10.1172/jci176230

N/A

0DataRank · unranked

31 citations

Pedro C. Barata, Andrew Elliott, Mehmet Asım Bilen, Earle F. Burgess, Toni K. Choueiri +16 more

Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma

Cell Reports(2024)10.1016/j.celrep.2024.114350

N/A

0DataRank · unranked

29 citations

Karl Semaan, Marc Eid, Ji-Heui Seo, Simon Garinet, Matthew P. Davidsohn +34 more

Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes

Journal of Clinical Oncology(2024)10.1200/jco.23.00699

N/A

0DataRank · unranked

25 citations

Valérie Gaborieau, Samuel M. Niman, Anush Mukeria, Xiaowen Liu, Krishna P. Maremanda +14 more

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

European Urology(2024)10.1016/j.eururo.2024.05.012

N/A

0DataRank · unranked

8 citations

Catherine M. Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell V. Meng +16 more

A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer

The Prostate(2024)10.1002/pros.24788

N/A

0DataRank · unranked

2 citations

Alok K. Tewari, D. Gulhan, Ziad Bakouny, Guruprasad Ananda, Hunter Savignano +8 more

AXL signaling in cancer: from molecular insights to targeted therapies

Signal Transduction and Targeted Therapy(2025)10.1038/s41392-024-02121-7

N/A

0DataRank · unranked

69 citations

Akansha Sharma, Ketki Patne, Saba Tabasum, Jyoti Suryavanshi, Laxminarayan Rawat +7 more

HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy

Cell(2025)10.1016/j.cell.2025.01.046

N/A

0DataRank · unranked

56 citations

David A. Braun, Karl R. Clauser, Vijyendra Ramesh, Nitin H. Shirole, Joseph E. Duke-Cohan +41 more

Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma

Cancer Discovery(2025)10.1158/2159-8290.cd-24-0991

N/A

0DataRank · unranked

38 citations

Lena V. Wirth, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

Selective HLA knockdown and PD-L1 expression prevent allogeneic CAR-NK cell rejection and enhance safety and anti-tumor responses in xenograft mice

Nature Communications(2025)10.1038/s41467-025-63863-8

N/A

0DataRank · unranked

16 citations

Mubin Tarannum, Yingjie Zhao, Yiming J. Zhang, James Dongjoo Ham, Kewen Lei +11 more

Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.13727

N/A

0DataRank · unranked

14 citations

Marc Machaalani, Razane El Hajj Chehade, Amin H. Nassar, Rashad Nawfal, Michael P. Manos +20 more

KIM-1 as a Prognostic Marker in Renal Cell Carcinoma

European Urology Focus(2025)10.1016/j.euf.2025.06.012

N/A

0DataRank · unranked

10 citations

Marc Machaalani, Joseph V. Bonventre, David F. McDermott, Toni K. Choueiri, Wenxin Xu +1 more

Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer

Nature Communications(2025)10.1038/s41467-025-60654-z

N/A

0DataRank · unranked

9 citations

Sheng-Yu Ku, Varadha Balaji Venkadakrishnan, Martin Bakht, Michael Sigouros, Joanna Chan +18 more

Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma

Immunity(2025)10.1016/j.immuni.2025.10.013

N/A

0DataRank · unranked

8 citations

Soki Kashima, Sabrina Y. Camp, Kevin Meli, Eddy Saad, Breanna Titchen +14 more

Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer

npj Precision Oncology(2025)10.1038/s41698-025-01031-3

N/A

0DataRank · unranked

7 citations

Rashad Nawfal, John Canniff, Hunter Savignano, Ji-Heui Seo, Stephanie Siegmund +17 more

Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress

Cancer Letters(2025)10.1016/j.canlet.2025.217984

N/A

0DataRank · unranked

3 citations

Marc Machaalani, Laxminarayan Rawat, Johannes Wedel, Saba Tabasum, Yuzuru Sasamoto +14 more

Humoral immune responses to the second dose of a COVID-19 mRNA vaccine in cancer patients undergoing treatment

Human Vaccines & Immunotherapeutics(2025)10.1080/21645515.2025.2570963

N/A

0DataRank · unranked

1 citations

Troy J. Kemp, Nancy Roche, Katarzyna Haynesworth, Sarah Loftus, Benjamin J. Borski +10 more

Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.437

N/A

0DataRank · unranked

13 citations

Sai Vikram Vemula, Robert J. Motzer, Aparna Chhibber, Deepthi Chowbene, Nahuel Perrot +7 more

Detection and monitoring of translocation renal cell carcinoma via plasma cell-free epigenomic profiling

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.08.31.673338

N/A

0DataRank · unranked

1 citations

Karl Semaan, Jiao Li, Ananthan Sadagopan, John Canniff, Noa Phillips +27 more

HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.09.09.675147

N/A

0DataRank · unranked

1 citations

Laura Stransky, Nikita Bhalerao, Nitin H. Shirole, Qinqin Jiang, Eddy Saad +15 more

Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infection

The Lancet Regional Health - Americas(2025)10.1016/j.lana.2025.101038

N/A

0DataRank · unranked

0 citations

Chih–Yuan Hsu, Sanjay Mishra, Elizabeth A. Griffiths, Brahm H. Segal, Clara Hwang +30 more

Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium

UNC Libraries(2025)10.17615/bna9-v350

N/A

0DataRank · unranked

0 citations

Sanjay Mishra, Karen Russell, Samuel M. Rubinstein, Blau, Sibel, Daniel Y. Reuben +39 more

Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma 3574

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.1362

N/A

0DataRank · unranked

0 citations

Miya B. Hugaboom, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs

Nature Communications(2025)10.1038/s41467-025-64983-x

N/A

0DataRank · unranked

4 citations

Pooneh Koochaki, Sayed Matar, Fatme Ghandour, Marc Machaalani, Eddy Saad +22 more

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer(2020)10.1002/cncr.33033

N/A

0DataRank · unranked

340 citations

Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi +26 more

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2063

N/A

0DataRank · unranked

243 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0941

N/A

0DataRank · unranked

138 citations

Solange Peters, Orestis A. Panagiotou, Dimpy P. Shah, Nicole M. Kuderer, Chih–Yuan Hsu +40 more

Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)

Cancer(2020)10.1002/cncr.33169

N/A

0DataRank · unranked

15 citations

Toni K. Choueiri, Marion Feuilly, Jie Meng, J. Lister, Florence Marteau +5 more

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Cancer Cell(2020)10.1016/j.ccell.2020.10.022

N/A

0DataRank · unranked

33 citations

David M. Aboulafia, Melissa Accordino, Jared D. Acoba, Manmeet S. Ahluwalia, Syed A. Ahmad +95 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps760

N/A

0DataRank · unranked

13 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +7 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5100

N/A

0DataRank · unranked

9 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint Inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.28.121806

N/A

0DataRank · unranked

3 citations

David A. Braun, Sachet A. Shukla, Wenting Pan, Xīn Gào, Yue Hou +47 more

Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.746

N/A

0DataRank · unranked

1 citations

Petra Ross‐Macdonald, Sachet A. Shukla, David A. Braun, Linan Song, Eliseo Veras +7 more

ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma

UNC Libraries(2020)10.17615/e32h-ct35

N/A

0DataRank · unranked

0 citations

Michael W. Kattan, Pheroze Tamboli, Samira A. Brooks, Joel S. Parker, Toni K. Choueiri +10 more

Post-acute COVID-19 syndrome

Nature Medicine(2021)10.1038/s41591-021-01283-z

N/A

0DataRank · unranked

5052 citations

Kartik Sehgal, Aakriti Gupta, Mahesh V. Madhavan, Claire McGroder, Jacob S. Stevens +29 more

Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic

JAMA Oncology(2021)10.1001/jamaoncol.2020.7600

N/A

0DataRank · unranked

279 citations

Marco Paciotti, Andrew Schmidt, Stuart R. Lipsitz, Toni K. Choueiri, Quoc‐Dien Trinh +1 more

Metabolic reprogramming in renal cancer: Events of a metabolic disease

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer(2021)10.1016/j.bbcan.2021.188559

N/A

0DataRank · unranked

224 citations

Murugabaskar Balan, Akash Sabarwal, Toni K. Choueiri, Soumitro Pal, Samik Chakraborty

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature Reviews Clinical Oncology(2021)10.1038/s41571-021-00487-z

N/A

0DataRank · unranked

140 citations

Justin F. Gainor, Aparna Hegde, Alison M. Schram, Giuseppe Curigliano, Sumanta K. Pal +19 more

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00582-9

N/A

0DataRank · unranked

126 citations

Mathias Viard, Michael Dean, Stefan Groha, David A. Braun, Chris Labaki +12 more

COVID-19 vaccination and breakthrough infections in patients with cancer

Annals of Oncology(2021)10.1016/j.annonc.2021.12.006

N/A

0DataRank · unranked

102 citations

Chris Labaki, Chih–Yuan Hsu, Ziad Bakouny, Nino Balanchivadze, Stephanie Berg +34 more

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2283

N/A

0DataRank · unranked

57 citations

Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer +16 more

Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors

European Journal of Cancer(2021)10.1016/j.ejca.2021.07.031

N/A

0DataRank · unranked

16 citations

Sarah E. Street, Ian A. Strohbehn, Meghan Lee, Sophia H. Zhao, Nifasha Rusibamayila +16 more

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma

BJUI Compass(2021)10.1002/bco2.125

N/A

0DataRank · unranked

15 citations

Talal El Zarif, Rohit Jain, William Paul Skelton, Dory Freeman, Catherine Curran +8 more

Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE)

Cancer Genetics(2021)10.1016/j.cancergen.2021.08.004

N/A

0DataRank · unranked

3 citations

William L. Hwang, Jimmy A. Guo, Hannah I. Hoffman, Matthew C. Abramowitz, Ziad El-Bakouny +24 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps366

N/A

0DataRank · unranked

26 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19

medRxiv(2021)10.1101/2021.02.05.21250953

N/A

0DataRank · unranked

19 citations

Jeffrey P. Henderson, Pankil Shah, Samuel M. Rubinstein, Michael J. Joyner, Toni K. Choueiri +16 more

PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps4596

N/A

0DataRank · unranked

10 citations

Se Eun Kim, Viraj A. Master, David F. McDermott, Sabina Signoretti, David Cella +15 more

Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer

JAMA Network Open(2022)10.1001/jamanetworkopen.2022.4304

N/A

0DataRank · unranked

72 citations

Sonya Reid, Benjamin French, Cassandra Hennessy, Clara Hwang, Na Tosha Gatson +95 more

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer

Journal of Clinical Investigation(2022)10.1172/jci161858

N/A

0DataRank · unranked

33 citations

Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh +34 more

Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.04.012

N/A

0DataRank · unranked

23 citations

Elio Adib, Nicole Weise, Catherine Curran, Tyler F. Stewart, Dory Freeman +9 more

Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study

Open Forum Infectious Diseases(2022)10.1093/ofid/ofac037

N/A

0DataRank · unranked

19 citations

Kyle T. Enriquez, Tianyi Sun, Elizabeth J. Klein, Maheen Z. Abidi, Shailesh Advani +52 more

Triethylene Glycol Can Be Predeployed as a Safe Virus-Killing Indoor Air Treatment

The Journal of Infectious Diseases(2022)10.1093/infdis/jiac394

N/A

0DataRank · unranked

6 citations

Toni K. Choueiri, Gediminas Mainelis, Gurumurthy Ramachandran, Donald W. Schaffner, Emanuel Goldman

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba4500

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +15 more

Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKI).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.381

N/A

0DataRank · unranked

0 citations

Matthew C. Mannino, Matthew L. Bootsma, Rory M. Bade, Meghan Wells, Jennifer L. Schehr +5 more

Germline variants associated with immunotherapy-related adverse events

medRxiv(2022)10.1101/2022.04.10.22273627

N/A

0DataRank · unranked

0 citations

Sarah Abou Alaiwi, Wenxin Xu, Vivek Naranbhai, Amin H. Nassar, Ziad Bakouny +26 more

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad155

N/A

0DataRank · unranked

56 citations

Amin H. Nassar, Gregory R. Pond, Tony Zhuang, Viraj A. Master, Bassel Nazha +50 more

Chromophobe renal cell carcinoma

Cancer Cell(2023)10.1016/j.ccell.2023.07.006

N/A

0DataRank · unranked

51 citations

Liang Cheng, A. Ari Hakimi, Toni K. Choueiri, David A. Braun, Elizabeth P. Henske

Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium

The Lancet Regional Health - Americas(2023)10.1016/j.lana.2023.100445

N/A

0DataRank · unranked

39 citations

Chris Labaki, Ziad Bakouny, Chih–Yuan Hsu, Andrew Schmidt, Gilberto Lopes +39 more

Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101189

N/A

0DataRank · unranked

39 citations

Thomas Denize, Ziad Bakouny, Chris Labaki, Breanna M. Titchen, Kevin Bi +13 more

PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2274

N/A

0DataRank · unranked

37 citations

Opeyemi A. Jegede, Sayed Matar, Nourhan El Ahmar, Destiny J. West, Emily Walton +16 more

Epigenomic charting and functional annotation of risk loci in renal cell carcinoma

Nature Communications(2023)10.1038/s41467-023-35833-5

N/A

0DataRank · unranked

34 citations

Sarah Abou Alaiwi, Sylvan C. Baca, Elio Adib, Rosario I. Corona, Ji-Heui Seo +31 more

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.100947

N/A

0DataRank · unranked

27 citations

Evan J. Lipson, Ludmila Danilova, Suzanne L. Topalian, Jaroslaw Jedrych, Ezra Baraban +10 more

Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma

medRxiv(2023)10.1101/2023.01.18.23284664

N/A

0DataRank · unranked

0 citations

Sabrina Y. Camp, Hoyin Chu, Ryan L. Collins, Riaz Gillani, Jihye Park +11 more

Data from Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells

(2023)10.1158/1078-0432.c.6530786.v1

N/A

0DataRank · unranked

0 citations

Zhouwei Zhang, Hannah Kimball, Fangfang Qu, Kyler Berlind, Konrad H. Stopsack +4 more

Data from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

(2023)10.1158/1078-0432.c.6529871

N/A

0DataRank · unranked

0 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Data from Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

(2023)10.1158/1535-7163.c.6542307

Top 100%

0DataRank

Top 100%0 citations

Lana Hamieh, Kathryn P. Gray, Aaron R. Thorner, André P. Fay, Kathryn D. Lasseter +8 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Annals of Oncology(2024)10.1016/j.annonc.2024.07.727

N/A

0DataRank · unranked

198 citations

Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes

Cancer Cell(2024)10.1016/j.ccell.2024.03.002

N/A

0DataRank · unranked

46 citations

Chris Labaki, Tejas Jammihal, Wanling Xie, Maxine Sun, Valisha Shah +19 more

Toni K. Choueiri

Indexed papers

Top data-sharing exemplar

Papers